|
Abnova’s LiquidCell™ is a non-invasive, negative enrichment system for depletion of white blood cells (WBCs) and enumeration and retrieval of circulating rare cells (CRCs). Three major subtypes of CRCs in translational research and clinical studies are circulating cells (CTCs), circulating progenitor cells (CPCs), and circulating fetal cells (CFCs). A challenge for market adoption of CRCs is the efficient and reproducible identification, single cell isolation and retrieval of highly pure and viable CRCs, with their applications supported by a wide repertoire of
standardized, GMP bioreagents.
LiquidCell™ platform utilizes AbBeads™, SuperSlide™, tyramide TYRx™ and chromogenic CHRx™ technologies to enable CRC isolation and detection. AbBeads™ are antibody functionalized magnetic beads for white blood cell (WBC) depletion while avoiding the concomitant loss of CRCs. SuperSlide™ is a specialty-coated, non-autofluorescent glass slide for maximal CRC capture and retention throughout the cell processing. TYRx™ utilizes tyramide fluorescence and horseradish peroxidase (HRP)-conjugated secondary antibody for signal enhancement of low-density proteins on CRCs. CHRx™ uses DAB and Fast Red chromogenic substrates combined with horseradish peroxidase (HRP) and alkaline phosphatase (AP) to deliver brown and red color staining of CRCs under visible light.
Monoclonal antibodies targeting the intracellular and cell surface proteins can be flexibly interchanged to accommodate the biomarker switch in disease progression. This results in highly pure and viable CRCs for downstream protein characterizations, gene analysis, and cell assays. CTC enumeration is currently the only FDA approved application as a prognostic marker in metastatic breast, prostate, and colorectal cancers. In contrast, effective single cell isolation and retrieval of CRCs will open up new clinical utilities in the diagnostic and pharmaceutical arena.
|
